In a new milestone move to boost Malaysia’s digital health growth, Duopharma Biotech Berhad is investing in Naluri Hidup Sdn Bhd, a local digital health services provider.
Duopharma Biotech’s investment will be done via a Series A funding round where Naluri will receive a total of US$500,000 from Duopharma Biotech to expand smart digital integrated health applications.
This follows an initial investment of US$250,000 by Duopharma Biotech via a Simple Agreement for Future Equity (“SAFE”) made in April 2020 for personalised digital holistic healthcare applications. Additionally, Duopharma Biotech, as the returning strategic investor, together with other international and local venture capital firms will enable Naluri, which is a local pioneer in digital therapeutics, to expand operations into the region and deepens its data science capabilities.
This partnership will also enable Duopharma Biotech to deliver evidence-based therapeutic interventions using Naluri’s digital therapeutics solution, designed to help people manage their chronic disease risks through structured multi-disciplinary behavioural and psychological coaching programmes.
Effective use of holistic therapeutics could double healthcare effectiveness when compared to a purely pharmacotherapeutic (medication only) approach and could also be four times more cost-efficient and increase accessibility to clinicians and other health and fitness experts online as well.
Congratulating Naluri on its US$5 million Series A funding round, Duopharma Biotech Group Managing Director, Leonard Ariff Abdul Shatar said: “The smart application of digital technologies to enhance the effectiveness of healthcare and achieve the objective of a healthier life for all is one of Duopharma Biotech’s strategic pillars.
“We are proud to be part of this latest milestone to empower homegrown health technologies. Indeed, the global coronavirus pandemic has compounded the vital need for concerted co-operative initiatives to promote better health for all.”
Moving ahead, Duopharma Biotech aims to accelerate the use of data science, predictive algorithms, device connectivity and disease monitoring to deliver multiple clinically significant health outcomes to help patients to get healthier. Duopharma Biotech is already developing various use cases by utilising Naluri’s proprietary technology platform.
Duopharma Biotech is today one of Malaysia’s leading pharmaceutical companies listed on Bursa Malaysia. It has core competencies in the pharmaceutical industry inclusive of manufacturing, research & development and commercialisation & marketing of over 300 generic drugs – among others, Omesec and Prelica as well as its consumer healthcare (CHC) products such as CHAMPS®, FLAVETTES®, PROVITON® and Uphamol.
The Company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners.
It owns and operates three manufacturing plants that are based in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiaries in the Philippines and Singapore and a representative office in Jakarta, Indonesia. – The Health
